• Amylyx Pharmaceuticals recently reported that it has fully enrolled and dosed all 78 participants in LUCIDITY, its pivotal Phase 3 trial of avexitide for post-bariatric hypoglycemia after Roux-en-Y gastric bypass surgery, with topline results expected in the third quarter of 2026.
• This milestone locks in a clear timeline toward potential FDA review of a first-in-class GLP-1 receptor antagonist in a condition with no approved therapies.
• We’ll now explore how completing LUCIDITY enrollment, backed by prior Breakthrough Therapy designations, may influence Amylyx’s broader investment narrative.

Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

Amylyx Pharmaceuticals Investment Narrative Recap

To own Amylyx today, you need to believe avexitide can become a first approved therapy in post bariatric hypoglycemia and eventually support a broader rare-disease platform. Fully enrolling LUCIDITY locks in the timing of the key near term catalyst, the Q3 2026 Phase 3 data, while also crystallizing the main risk: if results are not clearly positive, Amylyx could lose its lead PBH asset and path to its first meaningful product revenue.

The LUCIDITY completion update sits alongside Amylyx’s recent Q4 2025 results, which showed a full year net loss of US$144.7 million and no product revenue, underlining how dependent the story is on future avexitide data. With operating expenses at US$36.6 million last quarter and a cash balance of about US$317 million, investors are watching closely to see whether the PBH program can justify the ongoing spend before that runway tightens.

Yet investors should also be aware that if LUCIDITY underperforms expectations, the combination of ongoing cash burn and reliance on a single late stage asset could...

Amylyx Pharmaceuticals' narrative projects $107.8 million revenue and $23.1 million earnings by 2029. This implies an earnings increase of about $168 million from -$144.7 million today.

Uncover how Amylyx Pharmaceuticals' forecasts yield a $22.20 fair value, a 60% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already modeling only US$46.5 million of revenue by 2029 before this update, so if you are more cautious you might see LUCIDITY’s success and timing as even more critical than consensus assumes.

Explore 3 other fair value estimates on Amylyx Pharmaceuticals - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Amylyx Pharmaceuticals research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Amylyx Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amylyx Pharmaceuticals' overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.